[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"basedow-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:basedow-disease":38},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100602013",false,"NCT07117981","Describe the Progression of Inflammatory Orbitopathy and the Biological Progression of Patients Receiving Second-line Treatment","Treatment of Graves' Orbitopathy in Patients Failing Corticosteroid Therapy: Multicenter National Retrospective Study- Basedow","HZN-IIT","Inclusion Criteria:\n\n* Patients aged 18 and older with moderate to severe orbitopathy;\n* Patients followed in endocrinology with the goal of achieving euthyroidism;\n* Corticosteroid-resistant patients: patients who have received at least 3 weeks of treatment with 500 mg weekly corticosteroid boluses and have not shown improvement in the clinical activity score (CAS);\n* Corticosteroid-dependent patients: relapse with a CAS of 3 or higher when decreasing or stopping corticosteroid therapy;\n* Patients with a CAS ≥ 3 or CAS \\\u003C3 with moderate to severe orbitopathy (according to EUGOGO);\n* Patients treated with immunotherapy, biotherapy, or radiotherapy as second-line treatment;\n* Patients who are not opposed to the reuse of their health data.\n\nExclusion Criteria:\n\n* Patients who have undergone bone or fat decompression surgery;\n* Patients with severe corneal involvement (Grade B or C; NO SPECS classification);\n* Patients with optic neuropathy (Grade B and C; NO SPECS classification);\n* Patients who have received 1 gram corticosteroid boluses for dysthyroid orbitopathy;\n* Patients who have opposed the reuse of their health data.","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","OBSERVATIONAL","Describe the progression of inflammatory orbitopathy and the biological progression of patients receiving second-line treatment (immunosuppressants, radiotherapy, or biotherapy).",[24],"Basedow Disease","RECRUITING","2025-08-12",{"date":28,"type":29},"2025-08-15","ACTUAL",{"date":31,"type":29},"2024-11-01",{"date":33,"type":20},"2025-12",{"name":35,"class":36},"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts","OTHER",9,""]